期刊
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
卷 22, 期 24, 页码 -出版社
MDPI
DOI: 10.3390/ijms222413554
关键词
HLA-1; extracellular vesicles; immunopeptidome; antigen presentation; mass spectrometry; cancer immunology
The HLA-I system plays a crucial role in activating cytotoxic lymphocytes and immune attack against pathogen-infected and cancer cells. While the ligandome of cancer cell surface HLA class I molecules has been extensively studied, the ligandome of extracellular vesicles remains relatively undefined. Understanding this could advance immune-based therapeutic approaches for cancer treatment.
The Human Leukocyte Antigen class I (HLA-I) system is an essential part of the immune system that is fundamental to the successful activation of cytotoxic lymphocytes, and an effective subsequent immune attack against both pathogen-infected and cancer cells. The importance of cytotoxic T cell activity and ability to detect foreign cancer-related antigenic peptides has recently been highlighted by the successful application of monoclonal antibody-based checkpoint inhibitors as novel immune therapies. Thus, there is an increased interest in fully characterising the repertoire of peptides that are being presented to cytotoxic CD8+ T cells by cancer cells. However, HLA-I is also known to be present on the surface of extracellular vesicles, which are released by most if not all cancer cells. Whilst the peptide ligandome presented by cell surface HLA class I molecules on cancer cells has been studied extensively, the ligandome of extracellular vesicles remains relatively poorly defined. Here, we will describe the current understanding of the HLA-I peptide ligandome and its role on cancer-derived extracellular vesicles, and evaluate the aspects of the system that have the potential to advance immune-based therapeutic approaches for the effective treatment of cancer.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据